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Carotid stenting: Costs and Evidence Basis 259Conclusions: At present CAS is at best non-inferior to CEA in terms of clinical outcome. Cost
savings due to shorter admission are offset by the high costs associated with catheter-based
interventions. At present CAS should be restricted to controlled settings until clinical trials
have shown a substantial clinical benefit.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Stroke is among the most disabling chronic diseases and one
of the major causes of death in the Western world. In the
Netherlands, with a population of 16 million inhabitants,
around 12 per 1000 inhabitants suffer a stroke. In 2005 over
10 000 people died as a result of stroke representing 7.6% of
all deaths.1 The benefit of carotid endarterectomy (CEA)
over the best medical treatment has been clearly demon-
strated in patients with symptomatic carotid stenosis.2,3
The risk of stroke or death for symptomatic patients with
severe stenosis within 30 days of CEA was 6.8% in ECST
and 5.8% in NASCET. Carotid angioplasty combined with
stenting (CAS) is another treatment option.4,5 Theoretical
advantages of CAS include a reduced morbidity rate,
reduced overall cost, shortened hospitalization, and
improved long-term patency rates. These thus far unsub-
stantiated claims require vigorous scrutiny before imple-
menting CAS as an acceptable alternative to CEA.
At present, clinical trial results are showing equal or
inferior results in terms of technical success and clinical
outcome of CAS compared to CEA. Moreover, two recent
trials comparing CAS and CEA were stopped because of poor
angioplasty results.6,7 Another trial stopped after interim
results failed to prove the non-inferiority of CAS over CEA.8
Limited data are available on the health economic
impact of CAS. Inconsistent conclusions regarding the cost
benefits or positive health effects of the stenting procedure
have been reported.9e16
To obtain a clear answer to these urgent questions
regarding the merits of CAS, we developed a comprehensive
Markov type decision model. Our goals were to exploit the
currently available evidence and insights to evaluate the
balance between cost and effects of CAS versus CEA, and to
obtain insight in the main drivers of cost-effectiveness.
Materials and Methods
Cost-effectiveness model
A simulation model previously developed to describe the
course of symptomatic carotid artery stenosis was adapted
to comprise CAS as a treatment option.17 Within this Markov
model four different health states were defined, i.e.,
healthy (recently symptomatic), minor stroke, major stroke
and death. Each individual starts off in the healthy recently
symptomatic state and may transfer to one of the subse-
quent states. The impact of these transitions in terms of
health effects is accounted for by means of utility scores.
The actual utility values for the different health states
were based on previous publications.18,19 Multiplication of
survival time with the pertaining utility yields an estimateof so called Quality Adjusted Life Years (QALYs). Long-
term survival was modeled using the ECST trial data.
Outcomes
Peri-operative survival after CEA was modeled using the
ECST (>70% stenosis) and the Cochrane review data.3,20 For
CAS the global survey by Wholey and the results from Co-
chrane review were used.5,20 Only studies that treated
symptomatic patients were included from the Cochrane
review. In absence of actual data or evidence with regard
to long-term clinical outcome and re-intervention rates
after CAS at the outset we conservatively assumed these
would be similar regardless of the initial procedure.
Cost estimates
Procedural costs of CAS and CEA were obtained by analyzing
the resources used and operative procedures performed in
the University Medical Center Utrecht (UMCU) and the St.
Antonius Hospital, Nieuwegein, The Netherlands. Costs
were calculated for procedures without complications and
based on 26 procedures for CEA and 11 procedures for CAS.
Costs of materials used for CAS were based on 27
procedures. CEA was performed under general anesthesia
in an operating theatre with a staff of eight. Intracranial
circulation was monitored intra-operatively using trans-
cranial Doppler (TCD) and electroencephalography (EEG).
On average, patients were discharged 4 days after surgery,
with a total of 5 hospitalization days. CAS was performed in
an angio-room with only six staff. During CAS use of
cerebral protection was left at the discretion of the
attending interventionist. Patients were discharged the
day after the intervention, with a total of 2 hospitalization
days. For both procedures recovery took place in a medium
care unit.
Cost estimates associated with acute minor or major
stroke and cost of hospital stay were based on available
Dutch literature.21,22 The follow-up costs of stroke patients
(such as costs of rehabilitation, nursing home, physical ther-
apy) were also estimated based on published data.23e25 All
costs used were adjusted to the 2003 price level using
a health care price index published by Statistics Netherlands.
Costs and health effects were discounted at an annual dis-
count rate of 4%.26
Scenario and sensitivity analyses
To assess whether the balance between costs and effects
of CAS compared to CEA would turn out differently with
different assumptions, i.e., under different scenarios, we
used complication rates from published case series (com-
bined in the global CAS registry) and randomized
260 M.P. Janssen et al.controlled trials. In our analyses complication rates and
procedural costs were varied and their impact on the cost-
effectiveness evaluated. In the sensitivity analyses
changes in costs and effects as a function of peri-operative
complication and re-operation rates were assessed.
Results
Peri-operative complication rates for CEA and CAS including
their 95% confidence intervals from both sources are shown
in Fig. 1. Fig. 2 shows the cost breakdown for both CEA and
CAS. Detailed information on the cost per procedure is pro-
vided in Table 1. A CAS procedure on average costs V1 488
more than a CEA procedure. A major part of the cost of the
endarterectomy procedure is attributable to hospitaliza-
tion. An average of 5.7 hospitalization days after CEA ac-
counts for one third of the total procedural cost. The
costs of the stenting procedure can for a major part beMinor s
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Figure 1 Peri-operative incidence rates with 95% confidattributed to costs of materials used during the interven-
tion. The stents, catheters, and cerebral protection device
(CPD) account for two thirds of the total costs of the proce-
dure. The CPD accounts for one fifth of the total CAS proce-
dural costs.
Using the peri-operative complication rates from Fig. 1
and data from Tables 1 and 2, the cost-effectiveness of
CAS over CEA was calculated over a 10 year time period
for both the Cochrane review results (Scenario 1) and for
the ECST patients versus the Wholey global CAS registry
(Scenario 2). The estimated cost-effectiveness for each
scenario is marked in Fig. 3, together with a 95% confidence
region surrounding the estimates.
For each scenario the differences in costs are indicated
on the vertical axis and the differences in QALYs on the
horizontal axis. If the procedural costs for CAS become less,
or the number of complications decrease, resulting in
QALYs gained, the cost-effectiveness point estimate willtroke rates
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Table 2 Main model parameters
Description Units Mean
value
Complication rates
Probability of technical
failure during CAS5
Probability 1.11%
Re-operation rate
post CAS32
per year 0.68%
Re-operation rate post CEA3 per year 0.09%
Post operative major
stroke rate3
per year 0.43%
Post operative minor
stroke rate3
per year 0.66%
Myocardial infarction rate3 per year 1.59%
Survival parameters
Death hazard ratio given
stroke3
-/- 2.07
Death hazard ratio given
disabling stroke3
-/- 6.05
Death hazard ratio given
myocardial
3
-/- 2.09
0
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Figure 2 Cost breakdown of CAS and CEA.
Carotid stenting: Costs and Evidence Basis 261move towards the lower right quadrant and the CAS
procedure is to be preferred. Any point below the diagonal
line indicating the cost-effectiveness (CE) threshold, i.e.,
the amount society would be willing to spend in order to
gain one QALY, indicates that CAS compared to CEA is cost-
effective and CAS is to be preferred (as indicated by the
arrow). Conversely, any point above this line indicates that
CAS is not cost-effective.Table 1 Cost breakdown of CAS and CEA
Cost category Costs (V)
CAS CEA
Personnel (number of) 326 831
Radiology assistant (2) 86
TCD operator 30 53
Interventional radiologist (2) 164
Neurophysiologist 46 83
Nurse (2) 134
Anesthetist nurse 67
Anesthetist 165
Vascular surgeon (2) 330
Materials 3 088 453
Stent 1 132
Other materials 920
Protective device 1 029
Anesthesia 6 219
Materials used 234
Overheads 756 453
Investment and maintenance 124 125
Cleaning 2 9
Housing 33 105
Social affairs 14 36
Purchasing 182 27
Other overheads 400 150
Diagnostics 587 567
Laboratory 89 69
Cost duplex
and MRA
498 498
Recovery and hospital stay 743 1 708
Recovery 213 315
Nursing 530 1 394
TOTAL COST 5 500 4 012
infarction
Death hazard ratio given
myocardial infarction
and stroke3
-/- 3.09
Probability of death within 6
months after peri-operative
disabling stroke3
Probability 9.30%
Probability of death after
disabling stroke3
Probability 30.8%
Probability of death after
myocardial infarction3
Probability 22.6%
Cost parameters
Cost myocardial infarction33 V/Event 15 000
Cost acute major stroke22 V/Event 25 769
Cost major stoke follow up
(1st 6 months)22
V/6 months 18 781
Cost major stoke follow up
(after 6 months)21,23,24
V/6 months 8 017
Cost major stoke on death
within 6 months22
V/Event 7 779
Cost minor stoke follow up
(1st 6 months) 22
V/6 months 5 556
Cost minor stoke on death
within 6 months22
V/Event 4 146
Utility parameters
Myocardial infarction18 QALYs per year 0.88
Minor stroke19 QALYs per year 0.65
Major stroke19 QALYs per year 0.15
Death QALYs per year 0.00Uncertainty with respect to different model parameters
on the cost-effectiveness outcome can be evaluated by
means of simulation. The analyses show that even though
the point estimate of Scenario 2 (Wholey versus ECST)
indicates CAS to be cost-effective, there would still be
a 6.7% chance that the parameter in fact lies above the cost-
effectiveness threshold (Fig. 3). Notably, based on Scenario
-8,000
-4,000
0
4,000
8,000
-0.40 -0.20 0.00 0.20 0.40
QALYs CAS - QALYs CEA
C
o
s
t
 
C
A
S
 
-
 
C
o
s
t
 
C
E
A
 
(
€
)
Cochrane
symptomatic
Wholey vs ECST
CE threshold
(25,000 €/QALY)
CAS preferred
CEA
preferred
Figure 3 Cost-effectiveness of different scenarios.
262 M.P. Janssen et al.1 (outcome of the Cochrane review) we estimated that there
is a 0.3% chance that in fact CAS is cost-effective.
The results of the sensitivity analyses are shown inTable3.
Here the changes in costs and QALYs per percent change
in peri-operative complication rate are presented. In as-
sessing the impact of procedural costs, we particularly
looked at the procedural costs for CAS by assuming that
the use of a CPD would be optional, i.e., may or may
not be used. Without use of a CPD, costs of the CAS pro-
cedure decrease by 20%. Leaving out the CPD would move
all the estimates in Fig. 3 down V1 077 in the cost-effec-
tiveness plane. The cost impact for TCD use was shown to
be marginal. Clearly, peri-procedural major stroke and
death rates after CAS were the major (clinical) contribu-
tors to the differences in costs and effects.
Discussion
Our analyses show that the costs associated with CAS are
considerably higher than those of CEA. For CAS to become
cost-effective there should be a clear clinical benefit over
CEA. This benefit should both from a clinician’s and a health
economic point of view show up as a reduced number ofTable 3 Change in costs and effects per percent increase
in complication or re-intervention rates
Description Cost (V) Quality adjusted
life years
Re-intervention CAS 361 0.010
Peri-operative minor
stroke rate
59 0.028
Peri-operative major
stroke rate
1 051 0.059
Peri-operative death rate 42 0.068major strokes or deaths, as these complications have the
highest impact on health and cost. However, given the
presently available evidence there is a considerable likeli-
hood that CAS is not presently cost-effective.20 Moreover,
two European randomized clinical trials comparing the
effectiveness of CAS to CEA were stopped early because
of the high complication rates in the stenting arm.6,7 The
results of these trials are in marked contrast with the initial
case series published, once again endorsing that one should
be very careful with interpretation and drawing critical
conclusions from the latter.
With regard to costs, the standard hospitalization was
considered 5 days for CEA (including the intervention day)
which was significantly longer compared with our CAS group
(5 vs 2 days). This reflects the rather conservative practice
in the Netherlands at the time of data collection (2003).
Interestingly, several authors have reported on cost
reducing measures for CEA by operating in a day care
setting. Our current practice guidelines include a next-day
discharge for both CEA and CAS patients. Also, reducing ICU
cost and utilizing regional anesthesia are measures that
have been proposed for cost reduction.27e29 A reduction in
hospitalization time by three days would reduce the cost of
a CEA procedure by V740 (a decrease of 18% in procedural
costs). Clearly, these cost-reductions for CEA would require
further clinical benefits and reduction in material cost for
CAS to become a cost-effective alternative to CEA: it would
move both estimates shown in Fig. 3 up over a distance of
V740 along the vertical axis. This would further reduce
the likelihood of CAS being cost-effective.
The confidence intervals (CI) of the peri-operative major
stroke rates (the complication with the highest impact on
the cost-effectiveness outcome) from ECST are more than
4% (Fig. 1). Looking at the impact of this variability in terms
of cost and effects (V4 200 and 0.24 QALY, four times the
values shown in Table 3) it is clear that there is insufficient
evidence at present to accurately estimate the incremental
cost-effectiveness of CAS over CEA. However, even though
the exact estimate is uncertain, Fig. 3 indicates that on
basis of the trial data CAS is clearly not cost-effective. On
the other hand, if complication rates could for example
be proven to be as low as reported by Wholey, CAS could
become a (cost-)effective alternative to CEA. However,
we suggest interpreting this scenario with extreme caution
as such results are contradicted with current trial evidence:
the most recent results from the EVA-3S and SPACE trials
(both included in the Cochrane review) point in quite the op-
posite direction.7,8 Note also, that all results presented thus
far pertain to short-term outcomes. Our simulation model
showed a high sensitivity to post intervention complication
rates, a topic that has so far received only limited attention
when comparing the effectiveness of CAS with CEA.30 The
major randomized trials on carotid angioplasty are CAVATAS,
EVA-3S, SPACE, CREST and ICSS (CAVATAS-2) will have to fo-
cus on this issue.31 It will, however, take years before the
(long-term) results of these studies will become available.
To our knowledge, only few studies have investigated
the cost differential between CEA and CAS (Table 4). Most
studies are in line with our findings and indicate a higher
cost associated with CAS.9,12,14e16 In all of these studies
the stent and CPD costs clearly surpassed the personnel
and additional costs. With more competitive devices being
Table 4 Observational studies comparing costs of carotid angioplasty (and stenting) versus carotid endarterectomy
Author/year Origin Intervention
(# patients)
Objective Conclusion
Jordan 19989 Single center CEA(130) vs PTA (109) In-hospital costs PTA higher costs
Brooks 200110 Single center CEA (51) vs CAS (53) In-hospital costs and
follow-up (2 years)
CAS slightly higher costs
Gray 200211 Single center CEA (136) vs CAS (136) In-hospital costs and
follow-up (2 years)
CEA higher costs
Kilaru 200312 Single center
þ Literature
CEA (447) vs Literature In-hospital costs and
follow-up
CAS higher costs
Ecker 200413 Single center CEA (391) vs CAS (46) In-hospital costs No cost advantage for either
procedure
Park 200614 Single center CEA (48) vs CAS (46) In-hospital costs CAS higher costs
Pawaskar 200715 Single center CEA (31) vs CAS (31) In-hospital costs CAS higher costs
Wolf 200716 Single center CEA (30) vs CAS (30) In-hospital costs CAS higher costs
Carotid stenting: Costs and Evidence Basis 263approved for this condition, it may be that these high costs
will to some extent decrease in the near future. We also
identified, two studies that could not demonstrate a statis-
tically significant difference in cost between CAS and CEA.
Both studies did not include the routine use of distal CPD,
however.10,13 One study, by Gray et al. actually reported
lower costs associated with CAS vs CEA.11 This study also
did not include the routine use of CPD. As shown in Table
4, most reports on cost-effectiveness of CAS were single
center studies with small sample sizes. This and other
drawbacks such as use of tariffs would appear to suggest
that our study is the first to adequately analyze net costs
using outcome data from the large randomized controlled
trials on CAS versus CEA.
There are some limitations inherent to the present study.
Ours is a modeling study, which as a result relies on several
assumptions and model parameters that as such may give
rise to discussion. We feel, however, that we have carefully
presented and discussed these assumptions and, moreover,
have evaluated the impact on the results of our analyses.
We believe our findings suggest that CAS should be
considered experimental, especially as long-term safety
and durability are yet another source of concern and
uncertainty. Any difference in stroke incidence, either
because of re-stenosis or re-intervention, will have a major
impact on long-term procedural (cost-) effectiveness.
Clinicians and policy makers will hopefully recognize their
responsibility to keep enrolling patients in the ongoing
trials and not to use CAS ‘off-label’.
In conclusion, at present CAS is at best non-inferior to
CEA in terms of clinical outcome. The cost savings due to
shorter admission are offset by the high costs associated
with catheter-based interventions. CAS has to be advised
against in routine practice for patients with severe symp-
tomatic carotid artery stenosis and should be restricted to
controlled settings until clinical trials have shown
a substantial clinical benefit.
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